RxDoctor Payments Data

Katherine Heffelfinger

Acute Care · Madison, ALNPI 1780124115

Payments from drug & device makers

$609in general payments, 2019–2025

Across 50 payments — averaging $12.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$318
  • Johnson & Johnson$96
  • Pfizer$94
  • E.r. Squibb & Sons, L.L.C.$35
  • Otsuka America Pharmaceutical, Inc.$29
  • Gilead$21
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$609100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$609 in reported general payments places this provider in the 55th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$55,937
Medicare patients
254
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin18$22,963
EliquisApixaban22$16,020
SynthroidLevothyroxine Sodium16$913
Rosuvastatin Calcium54$715
Nebivolol Hcl12$639
Losartan Potassium56$620
Methylprednisolone70$507
Fenofibrate13$502
Levothyroxine Sodium66$494
Albuterol Sulfate HfaAlbuterol Sulfate24$485
Atorvastatin Calcium55$482
Potassium Chloride19$466
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$452
Metoprolol Succinate35$438
Duloxetine Hcl14$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$16,02022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 711 acute care providers in Alabama.

Other acute care in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →